Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
Clinical trial NCT04331093 · RECRUITING
Trial details
- NCT number
- NCT04331093
- Sponsor
- Di Wu
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-01
- Primary completion
- 2024-12-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.